mTOR Inhibitor RAD001 (Everolimus) Has...

Clinical Cancer Research 2009 / 02 Vol. 15; Iss. 5

mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor

Lane, H. A., Wood, J. M., McSheehy, P. M.J., Allegrini, P. R., Boulay, A., Brueggen, J., Littlewood-Evans, A., Maira, S.-M., Martiny-Baron, G., Schnell, C. R., Sini, P., O'Reilly, T.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
15
Language:
english
Journal:
Clinical Cancer Research
DOI:
10.1158/1078-0432.CCR-08-2057
Date:
February, 2009
File:
PDF, 560 KB
english, 2009
Conversion to is in progress
Conversion to is failed